ATOS vs. ETON, ZVRA, ANNX, ATXS, ALLO, AURA, ORKA, KMDA, ESPR, and ABVX
Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Eton Pharmaceuticals (ETON), Zevra Therapeutics (ZVRA), Annexon (ANNX), Astria Therapeutics (ATXS), Allogene Therapeutics (ALLO), Aura Biosciences (AURA), Oruka Therapeutics (ORKA), Kamada (KMDA), Esperion Therapeutics (ESPR), and ABIVAX Société Anonyme (ABVX). These companies are all part of the "pharmaceutical products" industry.
Atossa Therapeutics vs.
Atossa Therapeutics (NASDAQ:ATOS) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.
In the previous week, Eton Pharmaceuticals had 8 more articles in the media than Atossa Therapeutics. MarketBeat recorded 16 mentions for Eton Pharmaceuticals and 8 mentions for Atossa Therapeutics. Eton Pharmaceuticals' average media sentiment score of 0.33 beat Atossa Therapeutics' score of 0.24 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.
Atossa Therapeutics received 145 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. Likewise, 65.22% of users gave Atossa Therapeutics an outperform vote while only 65.07% of users gave Eton Pharmaceuticals an outperform vote.
Eton Pharmaceuticals has higher revenue and earnings than Atossa Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Atossa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Atossa Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. Atossa Therapeutics' return on equity of -35.74% beat Eton Pharmaceuticals' return on equity.
Atossa Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 7.6% of Atossa Therapeutics shares are held by insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Atossa Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 731.45%. Eton Pharmaceuticals has a consensus price target of $24.00, indicating a potential upside of 35.75%. Given Atossa Therapeutics' higher probable upside, equities research analysts clearly believe Atossa Therapeutics is more favorable than Eton Pharmaceuticals.
Summary
Eton Pharmaceuticals beats Atossa Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Atossa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atossa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATOS) was last updated on 2/1/2025 by MarketBeat.com Staff
Free ATOS Stock Alerts